The global contrast media injectors market size was valued at USD 1.19 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.4% from 2023 to 2030. The growth of the contrast media injectors market is attributed to the rising prevalence of chronic disorders, technological advancements, along with globally increasing demand for minimally invasive surgical procedures. The COVID-19 outbreak had a negative impact on the contrast media injectors market. Many radiology departments saw a rapid drop in imaging case volume during the COVID-19 pandemic, resulting in a slump in demand for contrast media injectors.
Most countries throughout the world have begun to reduce security regulations and resume certain elective treatments, indicating that the market will continue to develop during the projection period in the post pandemic era. Additionally, organizations are gaining knowledge in their end-to-end supply chains to reduce product prices and improve the quality and services associated with contrast media injectors. Such operational ideas help organizations save money by eliminating third-party expenses. These characteristics are projected to generate lucrative market growth prospects.
The number of diagnostic imaging tests such as X-rays, ultrasounds, and advanced imaging equipment such as CT scans, MRIs, and others has increased as the prevalence of long-term diseases and complex co-morbidities has increased. The ability of these tests to detect the need for the treatment/surgery in interventional procedures and perioperative imaging before surgeries would increase the number of contrast media procedures. Globally, chronic diseases are the primary cause of death, and many people are affected by complicated morbidities which are expected to spur the market growth.
In addition, according to a report by CDC, the incidence of heart failure is increasing in the U.S., and it is one of the leading causes of death in the country. In 2020, approximately 659,000 people died due to cardiovascular diseases in the U.S. Moreover, by 2030, the number of people with heart diseases is estimated to increase by 46.0%. In most cases, deaths due to these diseases can be avoided if diagnosed at an early stage. Hence, the increasing prevalence of long-term diseases and complex co-morbidities are the major drivers as it is leading to the growth in demand for contrast media injectors.
Rapid technological advancements, a rise in healthcare expenditure, along with improvement in the quality of patient care are some of the major factors contributing to the global boost in demand for minimally invasive surgeries. Contrast media injectors can assist surgeons in accurately inserting a contrast agent to reduce human errors and increase the accuracy & efficiency of the surgical procedure. Contrast media injectors play a crucial role in intraoperative interventional radiology and interventional cardiology. The availability of advanced injector systems for diagnosis and intraoperative imaging is likely to propel their adoption.
In addition, key advantages offered by minimally invasive surgeries include speedy recovery, smaller incisions, low risk of infections, reduced scarring, minimal loss of blood during the procedure, and shorter hospital stays. These benefits are anticipated to boost the market during the forecast period. Additionally, minimally invasive procedures conducted with contrast media injectors provide real-time imaging and high quality, for surgical or diagnostic procedures, which can create significant opportunities for the surgeons to perform the surgical procedures in the appropriate area, augmenting the overall market.
Additionally, a growing number of approvals for contrast media injectors by regulatory bodies, such as the U.S. FDA and the EU, is predicted to actively contribute to the market growth. Leading manufacturers are making major investments in the development of high-end systems to cater to the unmet needs of their customers. These companies launch advanced systems, which can provide high accuracy, efficiency, and reliability to healthcare professionals.
For instance, in November 2022, GE Healthcare announced an investment of USD 80 million to increase contrast media production capacity. By 2025, GE Healthcare aims to manufacture 30 million more doses of contrast media every year which is anticipated to boost the market growth in near future.
The injector systems led the market and accounted for more than 60.9% share of the global revenue in 2022. Contrast agents are delivered into the bloodstream of patients during CT, MRI, and angiogram imaging procedures, allowing for improved visualization of the contrast of fluids or structures within the body. CT injector systems, MRI injector systems, and cardiovascular/angiography injector systems are all examples of contrast media injector systems. Among all, the CT injector systems segment accounts for the greatest proportion of the contrast media injectors market. This is due to its widespread use in the detection and treatment of vascular disease, cancer, and orthopedic injuries and disorders. Moreover, technological advancements and the launch of new products are expected to propel the growth of the segment as well.
The consumables segment is expected to grow at the highest CAGR of 8.3% during the forecast period. The increased need for consumables to ensure safety and hygienic conditions during diagnostic procedures can be linked to this segment's high growth rate. Additionally, it is expected that recurring purchases of these consumables for radiology, interventional cardiology, and interventional radiology will boost the segment's share.as well. Additionally, higher adoption of contrast media injectors consumables, greater availability along with the increasing prevalence of chronic disorders worldwide is expected to spur the segment growth.
The single head injectors led the market and accounted for more than 44.0% share of the global revenue in 2022. Single head injectors are the most widely used injectors for angiography, CT, and MRI. These injectors involve the use of only one syringe for the delivery of contrast media. Single head injectors are used in angiography, while dual head injectors, equipped with two syringes, are mostly used in CT systems. Additionally, large application and low average selling price, single head injectors are the first choice of customers in emerging economies such as China, India, and Brazil due to budget constraints which is anticipated to spur the segment growth.
The syringeless injectors segment is expected to grow at the highest CAGR of 8.6% during the forecast period. Syringeless power injectors have recently become popular to cut down on contrast media waste. When considering the decreased cost and increased performance of the devices, the syringeless injector provided a cost savings of roughly $8 per patient which is expected to drive the segment growth. Several major manufacturers are concentrating their efforts on the introduction and development of syringeless injectors, which are expected to boost the market.
Radiology led the market and accounted for more than 47.1% share of the global revenue in 2022. Radiology involves the use of noninvasive imaging technologies such as CT and MRI scans to create highly comprehensive images. CT scanning involves the use of X-ray equipment to build a structure of cross-sectional pictures of the body to detect the source of a medical condition, especially in soft tissues whereas MRI technology involves the application of a magnetic field to create images of inside of a patient’s body. Contrast media injectors are used with CT and MRI to identify a broad range of health conditions such as breast cancer heart diseases, gastrointestinal conditions, broken bones, colon cancer, and blood clots. In addition, this segment is projected to grow at a lucrative rate owing to the noninvasive nature of radiology techniques and rise in prevalence of chronic diseases.
The interventional cardiology segment is anticipated to witness the fastest growth at CAGR of 8.3% over the forecast period. The rising prevalence of cardiac conditions such as stroke, heart attack, arrhythmia, and heart valve disorders are expected to drive segment growth. As the prevalence of cardiovascular disorders rises, so does the demand for interventional cardiac surgery for treatment and diagnosis. Additionally, increasing technological advancements along with the number of hospital admissions will further drive the segment growth.
The hospitals segment dominated the market and accounted for over 68.2% share of the global revenue in 2022, owing to increasing admissions of patients suffering from neurological disorders, cardiovascular diseases, and cancer. Hospitals are primary users of contrast media injectors, owing to their wide range of applications in radiology, interventional radiology, and interventional cardiology. Additionally, increasing focus on development of healthcare infrastructure in developing economies of Asia Pacific and Africa is expected to propel the segment growth.
The diagnostics centers are the second leading segment after hospitals accounted for more than 22.0% share of the global revenue in 2022. The rise in the number of private imaging centers (driven by the increased demand for diagnostic imaging and early diagnosis) and the shortage of imaging modalities in small and mid-scale hospitals are two significant reasons driving the growth of diagnostic imaging centers. The demand for angiography operations, which are utilized for diagnosis, treatment planning, and prevention of chronic illnesses, is expected to rise as people become more aware of these conditions.
North America dominated the market and accounted for over 38.4% share of global revenue in 2022. Presence of well-established healthcare facilities and easy availability of advanced technologies as well as high demand for diagnostic procedures in this region are expected to increase the number of inpatient examinations which is expected to boost the market growth. Additionally, countries such as the U.S. and Canada have seen an increase in hospital admissions in recent years, because of the high occurrence of chronic medical diseases & fatal injuries.
Chronic disease, for instance, is the leading cause of disability and mortality, according to CDC. In the U.S., four of ten adults have or two or more chronic diseases, and six of ten adults have a chronic disease. In addition, the Canadian Institute of Health (CIH) reported that over 17,655 persons were hospitalized in 2016 and 2017 owing to sports-related injuries.
Asia Pacific contrast media injectors market is likely to grow at 8.5%. Japan, China, and India are major contributors to Asia Pacific’s contrast media injectors market. Rapidly developing economies, growing awareness about healthcare, and aging population are among the key factors boosting the market in this region. Growing prevalence of chronic diseases, such as neurological disorders, and increasing geriatric population are factors expected to boost the demand for contrast media injectors. Moreover, neurological diseases are strongly associated with aging, and mostly begin in people aged 60 years and older. Thus, there is a high demand for advanced surgical treatment solutions for these diseases, which is expected to propel the demand for advanced contrast media injectors.
Some of the key players that dominated the global market in 2022 include Bayer HealthCare LLC, Bracco Group, Ulrich Medical, Guerbet Group, Medtron AG, Nemoto Kyorindo Co., Ltd., Hong Kong Medi Co Limited, and Others. They provide a broad range of advanced devices through their strong distribution and supply channels worldwide.
In addition, leading players are involved in mergers & acquisitions, new product launches, strategic collaborations, and regional expansions to gain the maximum revenue share in the sector. Mergers & acquisitions help companies to expand their businesses and regional presence. For instance, in December 2022, Ulrich medical and GE Healthcare announced an agreement to market a branded multi-dose contrast media injector in the U.S.Some prominent players in the contrast media injectors market include:
Bayer HealthCare LLC
Nemoto Kyorindo Co., Ltd.
Hong Kong Medi Co Limited
Market size value in 2023
USD 1.26 billion
Revenue forecast in 2030
USD 2.0 billion
CAGR of 7.4% from 2023 to 2030
Base year for estimation
2016 - 2021
2023 - 2030
Revenue in USD million and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, type, application, end use, region
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Denmark; Norway; Sweden; India; Singapore; South Korea; China; Japan; India; Australia; Thailand; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key companies profiled
Bayer Ag; Bracco Imaging S.p.A.; Ulrich medical; Guerbet; MEDTRON AG; Nemoto Kyorindo Co., Ltd.; Hong Kong Medi Co Limited
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2016 to 2030. For the purpose of this study, Grand View Research has segmented the global contrast media injectors market report on the basis of product, type, application, end use, and region:
Product Outlook (Revenue USD Million; 2016 - 2030)
CT injector systems
MRI injector systems
Cardiovascular/angiography injector systems
Type Outlook (Revenue USD Million; 2016 - 2030)
Single Head Injectors
CApplication Outlook (Revenue USD Million; 2016 - 2030)
End Use Outlook (Revenue USD Million; 2016 - 2030)
Ambulatory Surgery Centers
Regional Outlook (Revenue, USD Million, 2016 - 2030)
Middle East and Africa (MEA)
b. The global contrast media injectors market size was estimated at USD 1.19 billion in 2022 and is expected to reach USD 1.26 billion in 2023.
b. The global contrast media injectors market is expected to grow at a compound annual growth rate of 7.4% from 2023 to 2030 to reach USD 2.0 billion by 2030.
b. CT injector systems dominated the contrast media injectors market with a share of 53.7% in 2022. This is attributable to the rising widespread application of these systems in cancer surgery, neurosurgery, cardiovascular surgery, and spinal procedures.
b. Some key players operating in the contrast media injectors market include Bracco Group; Guerbet Group; Medtron AG; Bayer HealthCare LLC; Ulrich GmbH & Co. KG; Nemoto Kyorindo Co., Ltd.; GE Healthcare; VIVID IMAGING; Sino Medical-Device Technology Co., Ltd.; and APOLLO RT Co. Ltd.
b. Key factors that are driving the contrast media injectors market growth include technological advancements and increasing demand for minimally invasive surgeries.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."